How can CELLSEARCH® Circulating Tumor Cell Test help me in the treatment of my patients?
Monitoring your patients with serial CTC testing provides you with real-time prognostic information at any time during a patient's course of disease.
Changes in CTCs are predictive of disease progression among cancer patients receiving chemotherapy. The FDA-cleared CELLSEARCH® CTC Test aids in the monitoring of patients with metastatic breast, prostate*, or colorectal cancer.
Serial testing for circulating tumor cells (CTCs) should be used in conjunction with other clinical methods for monitoring, such as imaging, lab tests, physical examination, and complete medical history to assess patient prognosis throughout the course of disease.Review clinical trial data and real case studies showing the role of CTC testing in patient management
*Metastatic prostate cancer patients were defined as having two consecutive increases in the serum marker prostate-specific antigen above a reference level, despite standard hormonal management. These patients are commonly described as having androgen-independent, hormone-resistant, or castration-resistant prostate cancer. For more information on the intended use and limitations for the CELLSEARCH® Circulating Tumor Cell Test, please refer to the Instructions for Use which can be found at documents.cellsearchctc.com.